Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Leichsenring

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Genes, Chromosomes & Cancer|October 30, 2016
Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevanceNicole Pfarr, Roland Penzel, Volker Endris, et al.
Translational Lung Cancer Research|December 4, 2018
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and cliniciansMichael Allgäuer, Jan Budczies, Petros Christopoulos, et al.
Genes, Chromosomes & Cancer|September 20, 2018
Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker studyAnna-Lena Volckmar, Volker Endris, Matthias M Gaida, et al.
Genes, Chromosomes & Cancer|April 24, 2016
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survivalJan Budczies, Michael Bockmayr, Carsten Denkert, et al.
International Journal of Cancer|September 22, 2018
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysisIvo Buchhalter, Eugen Rempel, Volker Endris, et al.
International Journal of Cancer|January 24, 2020
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryTilmann Bochtler, Anna Reiling, Volker Endris, et al.
Genes, Chromosomes & Cancer|July 21, 2016
Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathwayAnna-Lena Volckmar, Jonas Leichsenring, Christa Flechtenmacher, et al.
Cancers|September 8, 2019
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer SamplesMartina Kirchner, Olaf Neumann, Anna-Lena Volckmar, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer|November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panelsVolker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Genes, Chromosomes & Cancer|October 30, 2016
Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevanceNicole Pfarr, Roland Penzel, Volker Endris, et al.
Translational Lung Cancer Research|December 4, 2018
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and cliniciansMichael Allgäuer, Jan Budczies, Petros Christopoulos, et al.
Genes, Chromosomes & Cancer|September 20, 2018
Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker studyAnna-Lena Volckmar, Volker Endris, Matthias M Gaida, et al.
Genes, Chromosomes & Cancer|April 24, 2016
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survivalJan Budczies, Michael Bockmayr, Carsten Denkert, et al.
International Journal of Cancer|September 22, 2018
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysisIvo Buchhalter, Eugen Rempel, Volker Endris, et al.
International Journal of Cancer|January 24, 2020
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryTilmann Bochtler, Anna Reiling, Volker Endris, et al.
Genes, Chromosomes & Cancer|July 21, 2016
Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathwayAnna-Lena Volckmar, Jonas Leichsenring, Christa Flechtenmacher, et al.
Cancers|September 8, 2019
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer SamplesMartina Kirchner, Olaf Neumann, Anna-Lena Volckmar, et al.
Cancers|January 24, 2019
Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor SurvivalPetros Christopoulos, Steffen Dietz, Martina Kirchner, et al.
International Journal of Cancer|November 18, 2018
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panelsVolker Endris, Ivo Buchhalter, Michael Allgäuer, et al.
Pageof 5